Validation of a transparent decision model to rate drug interactions

Abstract

BackgroundMultiple databases provide ratings of drug-drug interactions. The ratings are often based on different criteria and lack background information on the decision making process. User acceptance of rating systems could be improved by providing a transparent decision path for each category.MethodsWe rated 200 randomly selected potential drug-drug interactions by a transparent decision model developed by our team. The cases were generated from ward round observations and physicians’ queries from an outpatient setting. We compared our ratings to those assigned by a senior clinical pharmacologist and by a standard interaction database, and thus validated the model.ResultsThe decision model rated consistently with the standard database and the pharmacologist in 94 and 156 cases, respectively. In two cases the model decision required correction. Following removal of systematic model construction differences, the DM was fully consistent with other rating systems.ConclusionThe decision model reproducibly rates interactions and elucidates systematic differences. We propose to supply validated decision paths alongside the interaction rating to improve comprehensibility and to enable physicians to interpret the ratings in a clinical context.

Drug interaction databases in medical literature: transparency of ownership, funding, classification algorithms, level of documentation, and staff qualifications. A systematic review

“…While implementation of the suggestions made to standardization of evaluation of evidence and clinical consequences may resolve some of the discrepancies the importance of transparency cannot be underestimated [21][22][23]43]. Clinical health-care providers must have readily access to available overview of the algorithms and procedures of decision support systems.…”

Analysis of Drug-Drug Interactions in Swiss Claims Data Using Tizanidine and Ciprofloxacin as a Prototypical Contraindicated Combination

“…Interactions are ranked by severity using a validated decision model, which has been described in detail elsewhere. 19 Frequency analyses were carried out for 2014 data, and stratification for age, sex, and number of different drugs was performed. Similar results were expected for 2015 data.…”

Update on Direct Oral AntiCoagulants (DOACs)

“…Usually, a co-medication will influence these proteins, placing the DOACs in a "victim" role and unveiling a new dimension of possible interactions (50)(51)(52)(53)(54)(55)(56). Approximately seven percent of unwanted drug effects are due to drug interactions, and the incidence increases exponentially with the number of co-administered medications (29)(30). To receive fast and reliable information in clinical practice, the following web-based, independent providers are helpful: www.dosing.de or www.wechselwirkungscheck.de From a pharmacological view, the exposure of the co-administered drug at steady state is crucial.…”

“…Furthermore, approximately seven percent of the undesired effects associated with DOACS are due to drug interactions, with the incidence increasing along with the number of concomitant drugs (29,30).…”